Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07570940
PHASE4

A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery

Sponsor: Mayo Clinic

View on ClinicalTrials.gov

Summary

The purpose of this study is assess the incidence of postoperative atrial fibrillation (POAF) within one week of surgery in patients who receive pre-surgical stellate ganglion blockade with liposomal bupivacaine, compared to those receiving a saline placebo, using continuous electrocardiographic monitoring via wearable ECG devices.

Official title: Effectiveness Of Liposomal Bupivacaine Stellate Ganglion Blockade In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery: A Randomized Placebo-Controlled Trial

Key Details

Gender

All

Age Range

40 Years - Any

Study Type

INTERVENTIONAL

Enrollment

450

Start Date

2026-06

Completion Date

2030-06

Last Updated

2026-05-06

Healthy Volunteers

No

Interventions

DRUG

Liposomal bupivacaine

Patients undergoing isolated coronary artery bypass grafting will receive a stellate ganglion block using liposomal bupivacaine prior to surgery

DRUG

Placebo

Patients undergoing isolated coronary artery bypass grafting will receive a saline placebo injection to the stellate ganglion prior to surgery

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States